CIP2A expression and prognostic role in patients with esophageal adenocarcinoma

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Rantanen, Tuomo ^a,b   Kauttu, Tuuli ^c   Åkerla, Jonne ^d   Honkanen, Teemu ^b,d   Krogerus, Leena ^c   Salo, Jarmo ^c   Paavonen, Timo ^b,d   Oksala, Niku ^b  

^a SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

C MYC; CIP2A; Esophageal adenocarcinoma; Prognosis; Survival

Indexed keywords

MYC PROTEIN; PROTEIN; PROTEIN CIP2A; UNCLASSIFIED DRUG; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ARTICLE; BARRETT ESOPHAGUS; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE C MYC; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; ADULT; AGED; ESOPHAGUS TUMOR; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; MUCOSA; PATHOLOGY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIGENS; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84880970246     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0684-7     Document Type: Article

References (29)

1. Sihvo E, Salminen J, Rämö O, Salo J. The epidemiology of oesophageal adenocarcinoma: has the cancer of gastric cardia an influence on the rising incidence of oesophageal adenocarcinoma? Scand J Gastroenterol. 2000;35:1082-6.
2. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-31.
3. Ye W, Chow W, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux disease and after antireflux surgery. Gastroenterology. 2001;12:1286-93.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
5. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-MYC and negatively regulates c-MYC accumulation. Mol Cell Biol. 2006;26:2832-44.
6. Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51-62.
7. Katz J, Jakymiw A, Ducksworth M, Stewart C, Bhattacharyya I, Cha S, Chan E. CIP 2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther. 2010;107:694-9.
8. Böckelman C, Hagström J, Mäkinen LK, et al. High CIP2A immunoreactivity is an independent prognostic indicator in earlystage tongue cancer. Br J Cancer. 2011;104:1890-5.
9. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol. 2012;29:113-8.
10. Khanna A, Böckelman C, Hemmes A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793-805.
11. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722-8.
12. Grady W, Markowitz S. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101-28.
13. Teng H, Yang S, Lin J, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 2012;16:1037-47.
14. Dong Q, Wang Y, Dong X, Li Z, Tang Z, Cui Q, Wang E. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857-65.
15. Xu P, Xu X, Huang Q, Zhang Z, Zhang Y. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol. 2012;29:1643-7.
16. Liang M, Zhe-Sheng W, Zi L, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One. 2011;5:1-10.
17. Vaarala M, Väisänen M, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.
18. Ren J, Li W, Yan L, et al. Expression of CIP2A in renal cell carcinomas correlates with tumor invasion, metastasis and patients' survival. Br J Cancer. 2011;105:1905-11.
19. Böckelman C, Lassus H, Hemmes A, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 2011;105:989-95.
20. Huang L, Adelson M, Mordechai E, Trama J. CIP2A expression is elevated in cervical cancer. Cancer Biomark. 2010;8:309-17.
21. Come C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15: 5092-100.
22. Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert H. Frequent c-MYC amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. Am J Clin Pathol. 2001;115:835-40.
23. Tselepis C, Morris C, Wakelin D, et al. Upregulation of the oncogene c-MYC in Barrett's adenocarcinoma: induction of c-MYC by acidified bile acid in vitro. Gut. 2003;52:174-80.
24. Schmidt M, Meurer L, Volkweis B, Edelweiss M, Schirmer C, Kruel C, Gurski R. c-MYC overexpression is strongly associated with metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Dis Esophagus. 2007;20:212-6.
25. Lucas C, Harris R, Giannoudis A, Copland M, Slupsky J, Clark R. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;24:6660-8.
26. Sihvo E, Luostarinen M, Salo J. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol. 2004;99:419-24.
27. Rice T, Blackstone E, Rusch V. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-4.
28. Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumors of the digestive systems. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010.
29. Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C. CIKP2A overexpression is associated with c-MYC expression in colorectal cancer. Cancer Biol Ther. 2012;5:289-95.